Author:
Oróstica Karen Y.,Mohr Sebastian B.,Dehning Jonas,Bauer Simon,Medina-Ortiz David,Iftekhar Emil N.,Mujica Karen,Covarrubias Paulo C.,Ulloa Soledad,Castillo Andrés E.,Daza-Sánchez Anamaría,Verdugo Ricardo A.,Fernández Jorge,Olivera-Nappa Álvaro,Priesemann Viola,Contreras Seba
Abstract
AbstractGenomic surveillance (GS) programmes were crucial in identifying and quantifying the mutating patterns of SARS-CoV-2 during the COVID-19 pandemic. In this work, we develop a Bayesian framework to quantify the relative transmissibility of different variants tailored for regions with limited GS. We use it to study the relative transmissibility of SARS-CoV-2 variants in Chile. Among the 3443 SARS-CoV-2 genomes collected between January and June 2021, where sampling was designed to be representative, the Gamma (P.1), Lambda (C.37), Alpha (B.1.1.7), B.1.1.348, and B.1.1 lineages were predominant. We found that Lambda and Gamma variants’ reproduction numbers were 5% (95% CI: [1%, 14%]) and 16% (95% CI: [11%, 21%]) larger than Alpha’s, respectively. Besides, we observed a systematic mutation enrichment in the Spike gene for all circulating variants, which strongly correlated with variants’ transmissibility during the studied period (r = 0.93, p-value = 0.025). We also characterised the mutational signatures of local samples and their evolution over time and with the progress of vaccination, comparing them with those of samples collected in other regions worldwide. Altogether, our work provides a reliable method for quantifying variant transmissibility under subsampling and emphasises the importance of continuous genomic surveillance.
Funder
Agencia Nacional de Investigación y Desarrollo
Max-Planck-Gesellschaft
Netzwerk Universitätsmedizin
Bundesministerium für Bildung und Forschung
Deutsche Forschungsgemeinschaft
Max Planck Institute for Dynamics and Self-Organization (MPIDS)
Publisher
Springer Science and Business Media LLC
Reference88 articles.
1. Plante, J. A. et al. The variant gambit: COVID’s next move. Cell Host Microbe 29, 508 (2021).
2. Van Egeren, D. et al. Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. MedRxiv 2020, 11 (2020).
3. Singh, D. & Yi, S. V. On the origin and evolution of sars-cov-2. Exp. Mol. Med. 53(4), 537–547 (2021).
4. Rogozin, I. B. et al. Properties and mechanisms of deletions, insertions, and substitutions in the evolutionary history of sars-cov-2. Int. J. Mol. Sci. 25(7), 3696 (2024).
5. Thompson, R. N., Hill, E. M. & Julia, R. G. Sars-cov-2 incidence and vaccine escape. Lancet Infect. Dis. 21, 913 (2021).